Rodman & Renshaw Initiates Coverage On Cormedix With Buy Rating, Announces Price Target of $13
Rodman & Renshaw Initiates Coverage On Cormedix With Buy Rating, Announces Price Target of $13
羅德曼與任賽斯對cormedix進行買入評級，並宣佈目標股價爲13美元。
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Cormedix (NASDAQ:CRMD) with a Buy rating and announces Price Target of $13.
Rodman & Renshaw分析師Brandon Folkes開始對Cormedix (納斯達克:CRMD)進行買入評級，並宣佈價格目標爲$13。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。